Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Increase in Short Interest

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 630,577 shares, a growth of 300.2% from the January 15th total of 157,548 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 658,211 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 658,211 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.6% of the shares of the company are sold short.

Inventiva Stock Performance

Shares of NASDAQ:IVA traded up $0.01 during trading on Thursday, reaching $6.20. The stock had a trading volume of 211,461 shares, compared to its average volume of 551,305. Inventiva has a 1-year low of $2.40 and a 1-year high of $7.98. The business has a fifty day moving average price of $5.36 and a 200-day moving average price of $4.98.

Hedge Funds Weigh In On Inventiva

A number of institutional investors and hedge funds have recently bought and sold shares of IVA. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the last quarter. Creative Planning acquired a new position in Inventiva during the second quarter worth $32,000. Commonwealth Equity Services LLC grew its holdings in Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the 3rd quarter worth $116,000. Finally, Cerity Partners LLC purchased a new position in shares of Inventiva during the 4th quarter worth $93,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IVA shares. Guggenheim lowered their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. UBS Group initiated coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective for the company. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Barclays initiated coverage on Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target for the company. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Inventiva currently has an average rating of “Buy” and a consensus price target of $16.22.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.